Your browser doesn't support javascript.
loading
L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung, Soo-A; Lee, Dae-Hee; Moon, Jai-Hee; Hong, Seung-Woo; Shin, Jae-Sik; Hwang, Ih Yeon; Shin, Yu Jin; Kim, Jeong Hee; Gong, Eun-Yeung; Kim, Seung-Mi; Lee, Eun Young; Lee, Seul; Kim, Jeong Eun; Kim, Kyu-Pyo; Hong, Yong Sang; Lee, Jung Shin; Jin, Dong-Hoon; Kim, TaeWon; Lee, Wang Jae.
Afiliação
  • Jung SA; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Lee DH; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Moon JH; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Hong SW; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Shin JS; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Hwang IY; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Shin YJ; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Kim JH; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Gong EY; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Kim SM; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Lee EY; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Lee S; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Kim JE; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Kim KP; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Hong YS; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Lee JS; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea.
  • Jin DH; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea; Department of Convergence Medicine, University of Ulsan College of Medicine,
  • Kim T; Innovative Cancer Research, Asan Institute for Life Science, Republic of Korea; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympicro-43gil, Songpa-gu, Seoul, Republic of Korea. Electronic address: twkimmd@amc.seoul.kr.
  • Lee WJ; Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea.
Free Radic Biol Med ; 95: 200-8, 2016 06.
Article em En | MEDLINE | ID: mdl-27012422
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article